Stocknear Logo Stocknear
/
Popular
Login

Y-mAbs Therapeutics Inc.

4.79
0.29 (6.44%)
At close: Apr 02, 2025, 3:59 PM
4.80
0.10%
After-hours: Apr 02, 2025, 04:12 PM EDT
6.44%
Bid 4
Market Cap 216.82M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -0.67
PE Ratio (ttm) -7.16
Forward PE -11.65
Analyst Buy
Ask 5.98
Volume 194,663
Avg. Volume (20D) 426,698
Open 4.41
Previous Close 4.50
Day's Range 4.40 - 4.81
52-Week Range 4.25 - 17.78
Beta 0.65

About YMAB

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developin...

[Read more]
Industry Biotechnology
Sector Healthcare
IPO Date Sep 21, 2018
Employees 104
Stock Exchange NASDAQ
Ticker Symbol YMAB
Website https://www.ymabs.com
Full Company Profile

Analyst Forecast

According to 11 analyst ratings, the average rating for YMAB stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 317.10% from the latest price.

Stock Forecasts

Next Earnings Release

Y-mAbs Therapeutics Inc. is scheduled to release its earnings on May 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
3 months ago
-0.77%
Y-MAbs Therapeutics shares are trading higher afte... Unlock content with Pro Subscription
7 months ago
+10.63%
Y-mAbs Therapeutics shares are trading. The stock may be rebounding after falling earlier in the week on weak earnings and guidance.
news image

1 month ago · seekingalpha.com

Y-mAbs Therapeutics, Inc. (YMAB) Q4 2024 Earnings Call Transcript

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Courtney Dugan - Head-IR Michael Rossi - President & CEO Doug Gentilcore - Senio...

news image

4 weeks ago · zacks.com

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Lags Revenue Estimates

Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.02 per share a year ago.

news image

1 month ago · zacks.com

Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

YmAbs Therapeutics (YMAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news image

1 month ago · zacks.com

YmAbs Therapeutics (YMAB) Loses -25.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for YmAbs Therapeutics (YMAB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ...

news image

1 month ago · zacks.com

YmAbs Therapeutics (YMAB) Loses -26.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

YmAbs Therapeutics (YMAB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings ...

news image

2 months ago · seekingalpha.com

Y-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical Trials

YMAB's naxitamab sales declined from Q3 2023 to Q3 2024, but the company has a strong cash runway, supporting operations until 2027. Upcoming data readouts for GD2-SADA in Q2 2025 are critical for ass...

Create Price Alert on YMAB

Your price alert will notify you when the stock price is above 4.79.

Add to Watchlist